This project aims to transform a diuretic drug (amiloride) into a breast cancer drug that acts via a novel molecular mechanism.

The science of medicinal chemistry will be used to remove amiloride’s diuretic effects whilst gaining potent dual-activity against two breast cancer targets, uPA and NHE1.

Our study will validate a new pharmacological approach in cancer treatment and produce patented drugs suitable for development into first-in-class breast cancer drugs.


National Health and Medical Research Council

Scheme name

Project Grant

Years funded

2017 – 2019

Lead institution

University of Wollongong

Partner institution

Fujian Institute of Research on the Structure of Matter (China)